Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
656 participants
INTERVENTIONAL
2023-12-19
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ovaprene
Ovaprene
Non-hormonal intravaginal ring
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ovaprene
Non-hormonal intravaginal ring
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* General good health, by subject history and per investigator judgement
* Age 18 through 40 years, inclusive; approximately 66 subjects \>35 years old at visit 2 will be the Enrolled-Eligible Population
* In a relationship with a person assigned male at birth who meets eligibility criteria below.
--At least 18 years old, not known to be subfertile or infertile
* Have regular menstrual cycles (when not on hormonal contraception) with a usual length of 21 to 35 days, without heave bleeding that lasts longer than 5 days
* Be willing to stop their current method of contraception (with the exception of condoms) before Visit 2. Participants must experience at least one subsequent menstrual bleed before inserting Ovaprene. Participants using injectable contraception must be at least 9 months post their last dose at screening and have experienced at least 2 subsequent regular menstrual bleeds that were part of cycles of 21-35 days. After stopping their current method of contraception, subjects must either abstain fro vaginal sex or use condoms before inserting their first Ovaprene
* Not be actively desiring pregnancy for at least 13 months and be willing to accept an unknown risk of pregnancy
* Expect to engage in at least 4 acts of heterosexual vaginal intercourse per cycle during the study.
* Be willing to only use Ovaprene as the sole method of contraception over the course of the study
* Agree not to participate in any other clinical trials during the course of the study
* Be willing and able to comply with study procedures and to return to the clinic for scheduled follow-up visits
* Microbiota/innate immunity and colposcopy subsets only:
* Be willing to avoid vaginal sex and using tampons and other intravaginal products for 48 hours prior to clinic visits; and be willing to comply with subset procedures
Exclusion Criteria
* Have an allergy to the ingredients in Ovaprene
* Have a history of toxic shock syndrome
* Have a history of hereditary hemochromatosis
* Be breastfeeding an infant
* Have a history suggestive of infertility, defined as any of the following: known history of ectopic pregnancy or other fertility problem; sterilization/permanent contraception; endometriosis or hospitalization for pelvic inflammatory disease (PID) unless subject has had a subsequent spontaneous intrauterine pregnancy; or use of medications that could cause subfertility such as gonadotropin-releasing hormone agonists
* Currently have postcoital bleeding
* Have contraindications to pregnancy (medical condition) or chronic use of medications contraindicated in pregnancy
* Have a history of clinically significant uterine prolapse, cystocele, or rectocele that has required surgical intervention or pessary use
* Positive human immunodeficiency virus (HIV) test at screening
* Have exclusionary results on human papilloma virus (HPV) screening/cytology (subjects\>/=21 years old) at screening or require treatment or follow-up for an abnormal Pap smear or HPV test that would be needed during the study.
* Have had a vaginal or cervical biopsy within 1 month or vaginal surgery within the 3 months prior to screening
* Known current drug or alcohol abuse which, in the opinion of the investigator, could impact study compliance
* Have previously been included in the Enrolled-Eligible Population
* Is a direct employee or immediate family member of the Sponsor company, site Investigators or study staff
* Have taken any investigational drug or used any investigational device within the 30 days prior to screening
* Have a history of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or study treatment administration or could interfere with the interpretation of trial results
* Microbiota/innate immunity subset only:
--systemic use in the last 2 weeks prior to screening or anticipated use during the study of antibiotics (other than those used to treat urinary tract infection (UTI), candidiasis, or bacterial vaginosis(BV) diagnosed at Visit 1) or antivirals;
* If male partner has or is suspected to have had an HIV infection or other sexually transmitted infection
* if male partner has a known sensitivity or allergy to the ingredients in Ovaprene
* If male partner has previously participated in this study or has taken any investigational drug or used any investigational device within 30 days prior to the female subject's screening
* If the male partner has a history of any severe acute or chronic medical or psychiatric condition that could increase the risk associated with trial participation or could interfere with the interpretation of trial results.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Daré Bioscience, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine Mauck, MD
Role: STUDY_DIRECTOR
Daré Bioscience, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Precision Trials AZ
Phoenix, Arizona, United States
MomDoc Women's Health Research
Scottsdale, Arizona, United States
Del Sol Research Management, LLC
Tucson, Arizona, United States
Essential Health Access (Berkeley)
Berkeley, California, United States
Essential Access Health
Los Angeles, California, United States
Amicis Research Center
Newhall, California, United States
University of California at Davis
Sacramento, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Emory University
Atlanta, Georgia, United States
University of Hawaii
Honolulu, Hawaii, United States
Praetorian Pharmaceutical Research, LLC
Marrero, Louisiana, United States
The Johns Hopkins University
Baltimore, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
Washington University
St Louis, Missouri, United States
Rutgers Medical Center
Newark, New Jersey, United States
Columbia University
New York, New York, United States
Einstein College of Medicine
The Bronx, New York, United States
Carolina Women's Research and Wellness Center
Durham, North Carolina, United States
University of Cincinnati
Cincinnati, Ohio, United States
Case Western
Cleveland, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Pennsylvania Penn Obstetric Gynecology Associates
Philadelphia, Pennsylvania, United States
Magee-Women's Hospital
Pittsburgh, Pennsylvania, United States
University of Utah
Salt Lake City, Utah, United States
Eastern Virginia Medical School
Norfolk, Virginia, United States
Seattle Clinical Research Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DR-OVP-002
Identifier Type: -
Identifier Source: org_study_id